Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

DRSK vs CCOR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CCOR Wins Head-to-Head Institutional Verdict (0–0 across 6 Pillars · 2–1 Matrix Metrics)

CCOR Overall Winner 6-Pillar Tally: DRSK 0 – 0 CCOR (6 Tie) Matrix Metrics: DRSK 1 – 2 CCOR

As of Nov 16, 2026, Core Alternative Capital (CCOR) is the stronger overall head-to-head candidate over Aptus Defined Risk ETF (DRSK) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). DRSK carries a Unified Composite Score of 43.7/100 (HOLD) at $26.96 (N/M Forward P/E, N/A operating margin), whereas CCOR carries 45.4/100 (HOLD) at $27.66 (N/M Forward P/E, N/A operating margin).

  • Technical & Structure Timing Caution: DRSK is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 36.4); meanwhile CCOR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 66.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DRSK vs CCOR
DRSK Cboe BZX
Aptus Defined Risk ETF
Institutional Equity
$26.96
+0.07% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.32β · 5% Vol
Unified Composite Score
43.7 / 100 HOLD
Tech 31.0 Fund 51.0 Flow 50.0 Mom 70.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -1.9%) with fading momentum, RSI 36
RSI-14: 36.4 · SMA20: $27.19 · SMA50: $27.38
CCOR NYSE Arca Head-to-Head Winner
Core Alternative Capital
Institutional Equity
$27.66
+0.33% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.16β · 19% Vol
Unified Composite Score
45.4 / 100 HOLD
Tech 28.0 Fund 33.0 Flow 50.0 Mom 21.2
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (0.7% over 20 days), RSI 67
RSI-14: 66.5 · SMA20: $26.96 · SMA50: $26.13

6-Pillar Scorecard Institutional Category Breakdown (DRSK 0 – 0 CCOR)

Columns: Metric · DRSK · CCOR
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale Tie
Revenue Growth (YoY) N/A N/A
Earnings Growth (YoY) N/A N/A
TTM Revenue (USD) N/A N/A
Market Cap N/A N/A
3. Profitability & Quality Tie
Gross Margin N/A N/A
Operating Margin N/A N/A
Net Profit Margin N/A N/A
Return on Equity (ROE) N/A N/A
4. Balance Sheet & Cash Flow Tie
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 11.1% (50th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Distribution NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DRSK (1) vs CCOR (2)
Institutional Metric DRSK CCOR Criterion Row Edge
Market Capitalization
Scale
N/A N/A Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A N/A Higher Growth Tie
Operating Margin (TTM)
Profitability
N/A N/A Higher Margin Tie
Net Profit Margin
Profitability
N/A N/A Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
N/A N/A Higher ROE Tie
52-Week Range Position
Momentum
3% ($27–$30) 79% ($25–$28) Stronger Trend CCOR
Beta / 30D Volatility
Risk Regime
0.32β · 5% Vol -0.16β · 19% Vol Lower Realized Risk DRSK
Unified Institutional Score
Composite Signal
43.7 / 100 (HOLD) 45.4 / 100 (HOLD) Higher Composite CCOR
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CCOR +7.05 pp
DRSK: -1.06% · CCOR: +5.99%
3M Horizon CCOR +9.42 pp
DRSK: -5.37% · CCOR: +4.05%
6M Horizon CCOR +14.91 pp
DRSK: -7.19% · CCOR: +7.72%
1Y Horizon CCOR +13.31 pp
DRSK: -7.35% · CCOR: +5.96%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DRSK vs CCOR. Trailing 12-month operating profitability (DRSK N/A vs CCOR N/A) and valuation multiples (DRSK N/M vs CCOR N/M Forward P/E) are benchmarked directly in Pillar 4 below.

DRSK ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
CCOR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DRSK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact DRSK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CCOR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 11.1%
IV Percentile 50th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CCOR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DRSK Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CCOR Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ DRSK vs CCOR Key Questions & Quantitative Answers

As of Nov 16, 2026, Core Alternative Capital (CCOR) is the stronger overall head-to-head candidate over Aptus Defined Risk ETF (DRSK) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). DRSK carries a Unified Composite Score of 43.7/100 (HOLD) at $26.96 (N/M Forward P/E, N/A operating margin), whereas CCOR carries 45.4/100 (HOLD) at $27.66 (N/M Forward P/E, N/A operating margin). Technical & Structure Timing Caution: DRSK is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 36.4); meanwhile CCOR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 66.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DRSK and CCOR split Growth & Scale metrics: DRSK posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with CCOR at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, DRSK generates N/A in USD-normalized revenue versus N/A for CCOR. In operating R&D and SG&A reinvestment, DRSK deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CCOR.

DRSK and CCOR trade at balanced relative valuation multiples. DRSK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CCOR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DRSK (N/A ROE) versus CCOR (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, DRSK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.32β · 5% Vol realized risk). By comparison, CCOR carries 11.1% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.16β · 19% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.